DE | 23-3016883 | |
(State or Other Jurisdiction of | (I.R.S. Employer | |
Incorporation or Organization) | Identification No.) |
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act(17CFR240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act(17CFR240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act(17CFR240.13e-4(c))
Items to be Included in this Report
Royalties
The foregoing is a summary description of certain terms of the Amendment and, by its nature, is incomplete. The Company will file the Amendment as an exhibit to its Quarterly Report on Form 10-Q for the quarterly period ending June 30, 2005. All read ers are encouraged to read the entire text of the Amendment when it is filed. The Company's filings may be accessed electronically by means of the SEC's home page on the Internet at http://www.sec.gov or by means of the Company's home page on the Internet at http://www.auxilium.com under the heading "Investor Relations - SEC Filings."
The description of the Amendment in "Item 1.01. Entry into a Material Definitive Agreement" of this Report is incorporated into this Item 2.03 by reference. Such description is a summary of certain terms of the Amendment and, by its nature, is incomplete. The Company will file the Amendment as an exhibit to its Quarterly Report on Form 10-Q for the quarterly period ending June 30, 2005. All readers are encouraged to read the entire text of the Amendment when it is filed. The Company's filings may be accessed electronically by means of the SEC's home page on the Internet at http://www.sec.gov or by means of the Company's home page on the Internet at http://www.auxilium.com under the heading "Investor Relations - SEC Filings."
Auxilium Pharmaceuticals, Inc. | ||||||||
Date: May 16, 2005. | By: | /s/ Jennifer Evans Stacey | ||||||
Jennifer Evans Stacey | ||||||||
Executive Vice President, Secretary and General Counsel | ||||||||